Quick Search:

uzh logo
Browse by:

The deadline for the annual report 2015 is January 31st, 2016

Zurich Open Repository and Archive

Maintenance: Tuesday, 16.2.2015, 06:00-08:00

Maintenance work on various system components of ZORA. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-42081

Solovic, I; Sester, M; Gomez-Reino, J J; Rieder, H L; Ehlers, S; Milburn, H J; Kampmann, B; Hellmich, B; Groves, R; Schreiber, S; Wallis, R S; Sotgiu, G; Schölvinck, E H; Goletti, D; Zellweger, J P; Diel, R; Carmona, L; Bartalesi, F; Ravn, P; Bossink, A; Duarte, R; Erkens, C; Clark, J; Migliori, G B; Lange, C (2010). The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal, 36(5):1185-1206.

[img] PDF - Registered users only
View at publisher


Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-γ release assays or, as an alternative in individuals without a history of bacille Calmette-Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection with Mycobacterium tuberculosis. Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay, as there are insufficient data in children to recommend one test over the other. Consequently, targeted preventive chemotherapy is highly recommended for all individuals with persistent M. tuberculosis-specific immune responses undergoing TNF antagonist therapy as it significantly reduces the risk of progression to TB. This TBNET consensus statement summarises current knowledge and expert opinions and provides evidence-based recommendations to reduce the TB risk among candidates for TNF antagonist therapy.


162 citations in Web of Science®
178 citations in Scopus®
Google Scholar™



1 download since deposited on 12 Jan 2011
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Deposited On:12 Jan 2011 15:41
Last Modified:02 Jun 2015 07:23
Publisher:European Respiratory Society
Publisher DOI:10.1183/09031936.00028510
PubMed ID:20530046

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page